DeepMed Research

ALEXION PHARMACEUTICALS, INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public, Subsidiary

Established: 1992-01-01

Employees: 3.8K

Market Cap: -

Website: http://www.alexion.com

Clinical Trials

Early Ravulizumab Treatment Of Anti- AChR Antibody-Positive Generalized Myasthenia Gravis

Not yet recruiting

Conditions: Generalized Myasthenia Gravis
Anti-AChR Antibody Positive

Interventions: Drug: Ravulizumab

First Posted Date: 2025-05-13

Last Posted Date: 2025-05-13

Lead Sponsor: Alexion Pharmaceuticals, Inc.

Target Recruit Count: 40

Registration Number: NCT06967480

Locations: 🇮🇹
Clinical Trial Site, Torino, Italy

Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation

Phase 3

Recruiting

Conditions: Delayed Graft Function
DGF
Kidney Transplant

Interventions: Drug: Ravulizumab
Drug: Placebo

First Posted Date: 2025-02-17

Last Posted Date: 2025-05-21

Lead Sponsor: Alexion Pharmaceuticals, Inc.

Target Recruit Count: 450

Registration Number: NCT06830798

Locations: 🇬🇧
Research Site, Woodville South, United Kingdom

Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Eculizumab in Chinese Adults With gMG

Phase 3

Recruiting

Conditions: Generalized Myasthenia Gravis (gMG)
Refractory gMG

Interventions: Drug: Eculizumab

First Posted Date: 2025-01-08

Last Posted Date: 2025-01-17

Lead Sponsor: Alexion Pharmaceuticals, Inc.

Target Recruit Count: 15

Registration Number: NCT06764160

Locations: 🇨🇳
Research Site, Wuhan, China

Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation

Phase 2

Recruiting

Conditions: Antibody-Mediated Rejection
Kidney Transplantation
Biopsy-proven Histologic Scores
AMR

Interventions: Drug: ALXN2030
Drug: Placebo

First Posted Date: 2024-12-20

Last Posted Date: 2025-03-25

Lead Sponsor: Alexion Pharmaceuticals, Inc.

Target Recruit Count: 45

Registration Number: NCT06744647

Locations: 🇨🇳
Research Site, Taoyuan, Taiwan

Efficacy, Safety, PK, PD, and ADA of Eculizumab in Chinese Adults With NMOSD

Phase 3

Recruiting

Conditions: NMOSD
Neuromyelitis Optica Spectrum Disorders

Interventions: Drug: eculizumab

First Posted Date: 2024-12-09

Last Posted Date: 2025-05-07

Lead Sponsor: Alexion Pharmaceuticals, Inc.

Target Recruit Count: 21

Registration Number: NCT06724809

Locations: 🇨🇳
Research Site, Wuhan, China
🇨🇳
Research Site, Zhengzhou, China

PK Study of Gefurulimab SC in Healthy Chinese Adult Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: gefurulimab

First Posted Date: 2024-11-06

Last Posted Date: 2025-05-01

Lead Sponsor: Alexion Pharmaceuticals, Inc.

Target Recruit Count: 8

Registration Number: NCT06677138

Locations: 🇨🇳
Research Site, Shanghai, China

PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis

Phase 3

Recruiting

Conditions: Generalized Myasthenia Gravis
gMG

Interventions: Combination Product: Gefurulimab

First Posted Date: 2024-09-23

Last Posted Date: 2025-05-16

Lead Sponsor: Alexion Pharmaceuticals, Inc.

Target Recruit Count: 12

Registration Number: NCT06607627

Locations: 🇨🇳
Research Site, Taipei, Taiwan

Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Ravulizumab in Chinese Adults Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Phase 3

Active, not recruiting

Conditions: Paroxysmal Nocturnal Hemoglobinuria
PNH

Interventions: Drug: Ravulizumab

First Posted Date: 2024-08-30

Last Posted Date: 2025-03-06

Lead Sponsor: Alexion Pharmaceuticals, Inc.

Target Recruit Count: 18

Registration Number: NCT06578949

Locations: 🇨🇳
Research Site, Wuhan, China

Study of Danicopan as Add-on Treatment to Ravulizumab or Eculizumab in Pediatric Participants With PNH Who Have Clinically Significant Extravascular Hemolysis

Phase 3

Recruiting

Conditions: Paroxysmal Nocturnal Hemoglobinuria
PNH
Extravascular Hemolysis

Interventions: Drug: Danicopan

First Posted Date: 2024-06-07

Last Posted Date: 2025-03-07

Lead Sponsor: Alexion Pharmaceuticals, Inc.

Target Recruit Count: 6

Registration Number: NCT06449001

Locations: 🇫🇷
Research Site, Paris, France

Study of Ultomiris® (Ravulizumab) Safety in Pregnancy

Recruiting

Conditions: Ultomiris-exposed Pregnant/ Postpartum
Pregnancy
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Atypical Hemolytic Uremic Syndrome (aHUS)
Generalized Myasthenia Gravis (gMG)
Neuromyelitis Optica Spectrum Disorder (NMOSD)

First Posted Date: 2024-03-15

Last Posted Date: 2025-01-07

Lead Sponsor: Alexion Pharmaceuticals, Inc.

Target Recruit Count: 75

Registration Number: NCT06312644

Locations: 🇺🇸
North American call center (NACC), Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy